IDEXX Laboratories, Inc.
IDXX
$515.30
+0.71%
IDEXX Laboratories, Inc. develops, manufactures, and distributes diagnostic products, equipment, and services for companion animals and livestock, spanning in-clinic single-use test kits, benchtop chemistry and hematology analyzers, reference laboratory services, and veterinary practice management software. The company is the dominant global platform in veterinary diagnostics, with a razor-and-blade model that pairs instrument placements with high-margin consumables and recurring reference-lab revenue, and roughly 35% of revenue generated outside the United States. The current investor narrative centers on whether IDEXX can sustain its premium growth algorithm as veterinary clinic visit volumes normalize post-pandemic, with the most recent Q1 2026 print showing 14.3% revenue growth and management raising long-term guidance on higher clinical visits and diagnostic frequency. At the same time, the stock has de-rated sharply over the past year as investors debate the durability of companion-animal spending, competitive encroachment in point-of-care testing, and a valuation that still embeds decades of above-market compounding.…
IDXX
IDEXX Laboratories, Inc.
$515.30
Related headlines
Investment Opinion: Should I buy IDXX Today?
The synthesized recommendation is Hold, with a bias toward accumulation on further weakness. The core thesis is that IDEXX remains a high-quality compounder with 14.3% revenue growth, 63.35% gross margins, and 66% ROE, but the stock's 51.4x trailing PE and 2.31 PEG ratio leave little margin of safety until growth durability is confirmed. The analyst consensus of 'buy' with an average target of $698.92 implies 36.6% upside, but the wide target range of $470 to $805 signals unusually high uncertainty.
Supporting evidence for the Hold rating includes: (1) revenue growth of 14.26% YoY in Q1 2026, accelerating from prior quarters; (2) gross margin expansion to 63.35% from 62.44% a year ago, demonstrating pricing power; (3) TTM free cash flow of $1.08 billion and $351.0 million of Q1 2026 buybacks, funded entirely by internal cash generation; and (4) the stock trades at 12.6x TTM sales and 8.96x EV/Sales, which are rich absolute multiples but at multi-year lows for the company. The forward PE of 30.6x is more reasonable but still above the broader market, reflecting the premium for IDEXX's dominant market position and recurring revenue model.
The biggest risks that could invalidate the thesis are: (1) a deceleration in revenue growth below 10%, which would make the 51.4x PE unsustainable; (2) competitive encroachment in point-of-care diagnostics eroding market share; and (3) a high-beta market selloff disproportionately impacting the stock. The rating would upgrade to Buy if the stock breaks above resistance at $545-$560 with volume and revenue growth sustains above 12%, or if the PE compresses below 40x while growth remains intact. It would downgrade to Sell if revenue growth decelerates below 8% or if the stock breaks decisively below the 52-week low of $500.61. Relative to its own history, the stock is undervalued on a PS basis (12.6x vs. 69.7x in Q4 2021) but still expensive on a PEG basis, suggesting a fair value range of $550-$650.
Sign up to view all
IDXX 12-Month Price Forecast
IDEXX presents a classic growth-at-a-reasonable-price dilemma: the company is executing well with 14.3% revenue growth and expanding margins, but the stock's 51.4x trailing PE and 2.31 PEG ratio leave little room for error. The 36.6% gap to analyst targets suggests the selloff may have overshot, but the broken technical trend and persistent relative underperformance argue for caution until growth durability is confirmed. The base case (50% probability) sees the stock recovering toward $550-$700 as growth sustains, while the bear case (20%) risks a break below $500 if growth decelerates. I would upgrade to bullish if Q3 2026 revenue growth exceeds 14% with margin expansion, or downgrade to bearish if growth falls below 10% or the stock breaks below $500.61 on high volume.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on IDEXX Laboratories, Inc.'s 12-month outlook, with a consensus price target around $698.92 and implied upside of +35.6% versus the current price.
Average Target
$698.92
0 analysts
Implied Upside
+35.6%
vs. current price
Analyst Count
—
covering this stock
Price Range
$470 - $805
Analyst target range
Thirteen analysts cover IDEXX with a consensus recommendation of "buy" (recommendation mean of 2.21 on a scale where lower is more bullish), and the average target price of $698.92 implies roughly 36.6% upside from the current $511.65 — a strikingly wide gap that suggests the selloff has overshot fundamental value if the analysts are correct. The consensus leans bullish, with the institutional ratings history showing predominantly Buy/Overweight actions from Stifel, Barclays, BTIG, Morgan Stanley, and JP Morgan, while UBS and Piper Sandler have maintained Neutral ratings through 2026. Notably, there have been no downgrades in the visible ratings history — the actions are reiterations rather than changes — which means the bullish consensus has not yet been tested by a negative revision cycle, a risk if Q3 results disappoint. The target range is extremely wide, from a low of $470 (about 8% below the current price) to a high of $805 (about 57% above), a spread of $335 that signals unusually high uncertainty about the company's trajectory. The high target of $805 likely assumes a re-rating back toward the stock's historical premium multiple as revenue growth sustains in the low-to-mid teens and margins expand further, while the low target of $470 prices in continued multiple compression, decelerating clinic visit volumes, and competitive pressure in point-of-care diagnostics. The wide spread, combined with the fact that the stock is trading near its 52-week low while the average target sits 37% higher, creates a classic mean-reversion setup — but the absence of recent upgrades and the persistent relative underperformance suggest analysts may be lagging the market's repricing rather than leading it.
Bulls vs Bears: IDXX Investment Factors
The bear case currently has stronger evidence given the broken technical trend, persistent relative underperformance, and a PEG ratio of 2.31 that signals the stock is not cheap even after a 22% decline. However, the bull case rests on genuinely accelerating fundamentals: 14.3% revenue growth, expanding gross margins to 63.35%, and a 36.6% gap to analyst targets. The single most important tension is whether the market is correctly pricing a structural deceleration in veterinary clinic visits and diagnostic frequency, or whether it has overshot to the downside on a company still compounding revenue at double digits with 66% ROE. If Q3 2026 results confirm sustained low-to-mid-teens growth, the stock likely mean-reverts toward the $699 average target; if growth decelerates below 10%, the 51.4x PE could compress further toward the $470 low target.
Bullish
- Revenue growth accelerating to 14.3% YoY: Q1 2026 revenue of $1.141 billion grew 14.26% year-over-year, a sharp acceleration from the roughly 4-8% growth seen through much of 2024. This is the strongest growth rate in recent memory and management raised long-term guidance on higher clinical visits and diagnostic frequency.
- Elite profitability with expanding margins: Q1 2026 gross margin expanded to 63.35% from 62.44% a year earlier, while operating margin held above 31% for three consecutive quarters. Net margin of 24.4% and ROE of 66.0% are top-decile for the diagnostics sector.
- Analyst target implies 36.6% upside: Thirteen analysts have a consensus 'buy' rating with an average target price of $698.92, implying 36.6% upside from the current $511.65. The high target of $805 suggests 57% upside if the growth algorithm holds.
- Valuation multiples at multi-year lows: The trailing PE of 51.4x is near the low end of its multi-year band (down from 85.7x in Q4 2021), and the PS ratio of 12.6x is the lowest in the dataset's history. The market has already priced in significant multiple compression.
Bearish
- Broken technical trend near 52-week low: The stock is down 21.9% over the past year and 23.6% YTD, trading just 2.2% above its 52-week low of $500.61 and 33.5% below its 52-week high. The maximum drawdown of -34.17% confirms a sustained downtrend with persistent lower highs.
- PEG ratio of 2.31 signals expensive growth: Even after the selloff, the PEG ratio of 2.31 is well above the 2.0 threshold typically considered expensive. The forward PE of 30.6x on consensus EPS of $25.62 implies the market demands substantial earnings growth to justify the multiple.
- Severe relative underperformance vs. S&P 500: IDXX has underperformed SPY by 36.96% over 12 months, 10.97% over 3 months, and 8.03% over 1 month. This persistent underperformance indicates institutional distribution rather than a market-driven selloff.
- No analyst downgrades yet — revision risk: The bullish consensus has not been tested by a negative revision cycle, as visible ratings history shows only reiterations from Stifel, Barclays, BTIG, Morgan Stanley, and JP Morgan. If Q3 results disappoint, a wave of downgrades could accelerate the decline.
IDXX Technical Analysis
IDEXX is in a sustained downtrend, with the shares down 21.9% over the past year and 23.6% year-to-date, a stark underperformance versus the S&P 500's +15.0% 1-year and +11.7% YTD returns. At $511.65, the stock sits just 2.2% above its 52-week low of $500.61 and 33.5% below its 52-week high of $769.98, meaning it is trading at only about 2% of its 52-week range — a position that historically signals either deep value or an ongoing falling-knife dynamic, and the persistent lower highs argue for the latter until proven otherwise. The maximum drawdown of -34.17% confirms this is a broken trend rather than a routine pullback. Recent momentum remains negative and is diverging from an already weak longer-term trend: the stock is down 8.99% over the past month and 8.97% over three months, with the 1-month decline outpacing the 3-month decline only marginally, suggesting no stabilization yet. Relative strength is uniformly poor across every window — -8.03% versus SPY over 1 month, -10.97% over 3 months, and -36.96% over 12 months — indicating persistent institutional distribution rather than a market-driven selloff. The most recent session did bounce 1.02% off the prior close of $506.48, but with average volume of roughly 1.12 million shares and a short ratio of 3.41 days, there is no evidence of capitulation volume that typically marks durable bottoms. Key levels are clearly defined: support sits at the 52-week low of $500.61, and a decisive break below that level would open the door to further downside and likely trigger momentum-driven selling; resistance is layered at the $545-$560 area where the stock repeatedly failed in August and September, with the 52-week high of $769.98 as the longer-term ceiling. With a beta of 1.538, IDEXX is roughly 54% more volatile than the broader market, meaning position sizing should be materially smaller than a market-weight allocation and stop-loss discipline is essential — a 10% market drawdown could translate to a 15%+ move in this name.
Beta
1.54
1.54x market volatility
Max Drawdown
-34.2%
Largest decline past year
52-Week Range
$501-$770
Price range past year
Annual Return
-21.5%
Cumulative gain past year
| Period | IDXX Return | S&P 500 |
|---|---|---|
| 1m | -7.5% | +1.0% |
| 3m | -4.8% | +5.4% |
| 6m | -10.5% | +17.8% |
| 1y | -21.5% | +16.5% |
| ytd | -23.1% | +13.4% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
IDXX Fundamental Analysis
IDEXX's revenue trajectory remains healthy even as the stock struggles: Q1 2026 revenue of $1.141 billion grew 14.26% year-over-year, accelerating from the prior-year Q1 of $998.4 million, and the sequential cadence through 2025 ($1.091B in Q4, $1.105B in Q3, $1.109B in Q2) shows steady mid-single-digit sequential expansion. The revenue mix is balanced between product revenue of $666.1 million and service revenue of $474.7 million, with the consumables-and-services side providing the recurring, high-margin base that underpins the investment case. The growth rate is the strongest in recent memory — Q1 2026's 14.3% YoY compares favorably to the roughly 4-8% growth seen through much of 2024 — and this acceleration, combined with management's raised guidance, is the core bull argument that the market is currently refusing to reward. Profitability is exceptional: Q1 2026 net income was $278.4 million on a 24.4% net margin, with gross margin of 63.35% and operating margin of 31.78%, and the company has been profitable in every quarter shown. Gross margin has expanded from 62.44% in Q1 2025 to 63.35% in Q1 2026, and operating margin has held above 31% for three consecutive quarters, demonstrating pricing power and operating leverage. The one soft spot is Q4 2025, when gross margin dipped to 60.35% and operating margin to 28.94% on higher cost of revenue of $432.5 million, but the Q1 2026 rebound to 63.35% gross margin suggests that was seasonal or transitory rather than structural. The balance sheet is solid but not fortress-like: debt-to-equity of 0.671 and a current ratio of 1.167 provide adequate but not abundant liquidity, while ROE of 66.0% and ROA of 27.1% are elite returns on capital that reflect the asset-light, high-margin nature of the diagnostics franchise. Free cash flow is robust at $1.08 billion TTM, with Q1 2026 free cash flow of $234.3 million on operating cash flow of $266.2 million, and the company is aggressively returning capital — $351.0 million of stock repurchased in Q1 2026 alone against $132.0 million of debt repayment. The FCF yield of roughly 2.0% (on a $54.2 billion market cap) is low in absolute terms, but the internal cash generation comfortably funds capex of just $32.0 million per quarter, meaning IDEXX does not depend on external financing and has ample capacity for continued buybacks.
Quarterly Revenue
$1.1B
2026-03
Revenue YoY Growth
+14.3%
YoY Comparison
Gross Margin
63.3%
Latest Quarter
Free Cash Flow
$1.1B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is IDXX Overvalued?
Because IDEXX is solidly profitable — Q1 2026 net income of $278.4 million and trailing EPS positive — the PE ratio is the appropriate primary metric, and the stock trades at a trailing PE of 51.4x versus a forward PE of 30.6x. The wide gap between trailing and forward multiples implies the market expects substantial earnings growth, with consensus EPS of $25.62 for the forward period versus the current run-rate, and this steep expected growth is precisely what the stock's 22% one-year decline is questioning. On a price-to-sales basis, the stock trades at 12.6x TTM sales and 8.96x EV/Sales, while EV/EBITDA stands at 37.5x — all rich absolute multiples that only make sense if the growth algorithm holds. Relative to the broader Medical-Diagnostics & Research industry, IDEXX's 51.4x trailing PE and 12.6x PS represent a substantial premium, though precise peer averages are not provided in the data; the premium is justified by IDEXX's 63.4% gross margin, 24.4% net margin, and 66.0% ROE, which are top-decile for the sector. The PEG ratio of 2.31, however, signals that even after the selloff the stock is not cheap relative to its growth rate — a PEG above 2.0 is typically considered expensive, and this is the crux of the bear case. Historically, IDEXX's PE has compressed dramatically: it traded at 85.7x in Q4 2021, 59.3x in Q4 2023, 54.6x in Q4 2025, and now 51.4x, while its PS ratio has fallen from 69.7x in Q4 2021 to 12.6x today. The current 51.4x PE is near the low end of its multi-year band, and the 12.6x PS is the lowest in the dataset's history, suggesting the market has already priced in significant multiple compression — the question is whether earnings growth can now do the work that multiple expansion once did. The PB ratio of 33.8x remains elevated in absolute terms but is down from 80.9x in Q4 2021, reflecting both the price decline and accumulated retained earnings.
PE
51.4x
Latest Quarter
vs. Historical
Mid-Range
5-Year PE Range 35x~75x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
37.5x
Enterprise Value Multiple
Investment Risk Disclosure
Financial and operational risks center on the stock's premium valuation and the earnings growth required to justify it. The trailing PE of 51.4x and forward PE of 30.6x embed consensus EPS of $25.62, meaning any shortfall in earnings growth could trigger sharp multiple compression. The balance sheet is solid but not fortress-like, with debt-to-equity of 0.671 and a current ratio of 1.167 providing adequate but not abundant liquidity. The Q4 2025 gross margin dip to 60.35% and operating margin to 28.94% on higher cost of revenue of $432.5 million shows that margin volatility remains a risk, even though Q1 2026 rebounded to 63.35%. Additionally, roughly 35% of revenue is generated outside the United States, exposing the company to currency fluctuations and international market risks.
Market and competitive risks are significant given the stock's high beta of 1.538 and its premium valuation relative to the broader Medical-Diagnostics & Research industry. The PEG ratio of 2.31 indicates the market is paying a premium for growth that may not materialize if veterinary clinic visit volumes normalize post-pandemic. Competitive encroachment in point-of-care testing could pressure IDEXX's razor-and-blade model, and the absence of recent analyst upgrades suggests the bullish consensus may be lagging the market's repricing. The stock's 36.96% underperformance versus SPY over 12 months highlights the risk of continued sector rotation away from high-multiple healthcare names.
The worst-case scenario would involve a combination of decelerating revenue growth below 10%, margin compression from competitive pressure, and a broader market selloff that disproportionately impacts high-beta names. In this scenario, the stock could retest its 52-week low of $500.61, representing a 2.2% decline from the current price, but a more severe outcome could see it fall to the analyst low target of $470, an 8.1% decline. If the market re-rates IDEXX toward a lower multiple consistent with mid-single-digit growth, the stock could potentially decline 20-30% from current levels, approaching the $360-$410 range. The maximum drawdown of -34.17% over the past year provides a historical precedent for the magnitude of loss possible in an adverse scenario.
FAQ
The key risks of holding IDXX are: (1) Valuation risk — the 51.4x trailing PE and 2.31 PEG ratio leave little margin of safety, and any growth disappointment could trigger sharp multiple compression; (2) Competitive risk — encroachment in point-of-care diagnostics could pressure IDEXX's razor-and-blade model and erode market share; (3) Macro risk — with a beta of 1.538, the stock is 54% more volatile than the market, and a 10% market drawdown could translate to a 15%+ decline; and (4) Company-specific risk — the absence of recent analyst downgrades means the bullish consensus has not been tested, and a negative revision cycle could accelerate the decline. The most severe risk is a break below the 52-week low of $500.61, which could lead to a test of the $470 analyst low target.
The 12-month forecast for IDXX includes three scenarios: a bull case (30% probability) targeting $700-$805 if revenue growth sustains above 14% and the market re-rates the stock toward its historical premium multiple; a base case (50% probability) targeting $550-$700 as growth remains in the low-double-digits and the stock gradually recovers toward the analyst average target of $698.92; and a bear case (20% probability) targeting $470-$500 if revenue growth decelerates below 10% and the stock breaks below its 52-week low. The base case is most likely, assuming revenue growth remains between 10-14% YoY, gross margin stays above 62%, and no major competitive disruption occurs. The key assumption behind the base case is that veterinary clinic visit volumes normalize at higher levels and diagnostic frequency continues to increase.
IDXX appears fairly valued to slightly overvalued on absolute metrics but undervalued relative to its own history. The trailing PE of 51.4x is near the low end of its multi-year band (down from 85.7x in Q4 2021), and the PS ratio of 12.6x is the lowest in the dataset's history. However, the PEG ratio of 2.31 signals the stock is still expensive relative to its growth rate, and the forward PE of 30.6x is above the broader market. The market is pricing in substantial earnings growth, with consensus EPS of $25.62 for the forward period. If IDEXX delivers on this growth, the stock could re-rate toward the $699 average target; if growth disappoints, the multiple could compress further toward the $470 low target.
IDXX is a good buy for long-term growth investors who can tolerate volatility and have a 3-5 year horizon, but it is not a compelling value play at current levels. The stock trades at 51.4x trailing earnings and 30.6x forward earnings, with a PEG ratio of 2.31, which is expensive relative to its growth rate. However, the company is executing well with 14.3% revenue growth, 63.35% gross margins, and 66% ROE, and the analyst average target of $698.92 implies 36.6% upside. The biggest downside risk is a break below the 52-week low of $500.61, which could lead to a test of the $470 analyst low target. For risk-averse investors, waiting for a confirmed breakout above $545-$560 or a pullback to the $470-$500 range would offer a better risk/reward.
IDXX is more suitable for long-term investment (3-5 years) than short-term trading, given its high beta of 1.538, broken technical trend, and premium valuation. The company's strong fundamentals — 14.3% revenue growth, 63.35% gross margins, 66% ROE, and $1.08 billion TTM free cash flow — support a long-term compounding thesis, but the stock's 21.9% one-year decline and 36.96% relative underperformance versus SPY suggest near-term volatility will persist. Short-term traders could exploit the defined support at $500.61 and resistance at $545-$560, but the risk/reward is unfavorable without a confirmed trend reversal. A minimum holding period of 3 years is recommended to allow the growth algorithm to play out and for the valuation to normalize.